Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NeoVax melanoma vaccine |
| Synonyms | |
| Therapy Description |
NeoVax melanoma vaccine combines patient-derived melanoma neoantigen with the immunostimulant poly-ICLC, which stimulates anti-tumor immune response against tumor cells expressing the neoantigen (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NeoVax melanoma vaccine | NeoVax melanoma vaccine combines patient-derived melanoma neoantigen with the immunostimulant poly-ICLC, which stimulates anti-tumor immune response against tumor cells expressing the neoantigen (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01970358 | Phase I | NeoVax melanoma vaccine | A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | Completed | USA | 0 |
| NCT02129075 | Phase II | NeoVax melanoma vaccine CDX-301 Rasdegafusp alfa | CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma | Completed | USA | 0 |